|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
DECEMBER 20, 2004
By Gene G. Marcial A Ruddy Glow At USANA  When USANA Health Sciences (USNA
) fell to the low 20s in April, Jason Schrotberger of Turner Investment Partners snapped up shares -- convinced that demand for its nutritional supplements would ramp up. He was right: The stock popped to 35 in October as sales of its products -- including adult vitamins with Mega Antioxidant -- jumped. USANA also makes skin products, accounting for 15% of sales.
Scott Van Winkle of investment bank Adams Harkness, which has done business with USANA, notes that USANA, like Avon Products (AVP ), hires "associates" to sell direct to customers. Van Winkle, who rates the stock, now at 30.50, a buy, sees 2004 revenue growth of 35%, to $269 million, and earnings of $1.46 a share. For 2005, he expects $308.5 million and $1.80. Van Winkle is upbeat on USANA's reformulated skin-care product, Senseacute;, which will be marketed as being free of harmful chemicals. When it launches in 2005, he expects sales to rocket. (His 2005 earnings figure doesn't include Senseacute;.) Turner's Schrotberger sees higher 2005 earnings -- of $1.85 to $1.90 a share. For 2006, he forecasts $2.50, which includes projected Senseacute; sales. His price target: 40 to 45 in 2005 and 60 in 2006. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  See Gene on Fridays at 1:20 p.m. EST on CNNfn's The Money Gang.
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2004, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version
